The company said, “Staar’s (STAA) net sales have declined over the last two years. While management is aggressively executing a plan to return to growth in 2026, the fact is that market dynamics result in a significantly lower growth profile – which negatively impacts valuation.” Guidance taken from the company’s presentation outlining that the proposed merger with Alcon (ALC) is in the best interests of Staar and its stockholders.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STAA:
- Staar Surgical Announces Proposed Merger with Alcon
- Staar Surgical reports expiration of window shop period under Alcon merger pact
- Yunqi Capital intends to vote against STAAR Surgical sale to Alcon
- Staar Surgical issues letter to stockholders regarding Alcon merger
- STAAR Surgical Announces Merger with Alcon